PolyPid $PYPD

Health Care · NASDAQ

Israel
$6.12
-0.43 (-6.56%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 27, 2026, the first target we tracked for PYPD.

PolyPid (PYPD) is trading down at $6.12 (-6.56%) on NASDAQ, as of the latest quote. It operates in the Health Care sector.

IPO: June 26, 2020 · $16.00 offering · NASDAQ

Analyst price targets on PYPD

One firm's current price target on PolyPid: $10 — 63% above the current $6.12. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateOct 27, 2026 FirmOppenheimer RatingOutperform · initiates Targetat $5.77 · $10 +73% Horizonby Oct 2027 StatusOpen

Entry price $5.77, the close nearest Oct 27, 2026, when the target was reported; the target is +73% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 27, 2027.

Source Oppenheimer initiates PolyPid stock coverage with outperform rating Investing.com · Oct 27, 2026 · opens the publisher's site
Oppenheimer initiated coverage on PolyPid Ltd. with an outperform rating and a price target of $10.00.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

PolyPid net income history (FY2018–FY2025)

Net income
$5.92M−$18.3M−$42.6MFY2018 net income: $5.92M'18FY2019 net income: −$6.91M'19FY2020 net income: −$36.9M'20FY2021 net income: −$42.6M'21FY2022 net income: −$39.6M'22FY2023 net income: −$23.9M'23FY2024 net income: −$29.0M'24FY2025 net income: −$34.2M'25
PolyPid annual financial statements
FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Operating income−$18.4M−$18.6M−$26.3M−$43.1M−$38.9M−$22.9M−$28.0M−$33.0M
Net income$5.92M−$6.91M−$36.9M−$42.6M−$39.6M−$23.9M−$29.0M−$34.2M
EPS (diluted)$25.80$710.70$134.40$68.27$61.09$16.93$4.91$2.09
Balance sheet
Cash and equivalents$7.77M$3.92M$4.32M$9.82M$8.55M$5.31M$15.6M$6.40M
Total assets—$33.8M$75.8M$44.2M$26.0M$15.4M$25.2M$22.3M
Total liabilities—$121.4M$3.07M$8.28M$20.1M$17.5M$17.5M$11.3M
Long-term debt————$7.57M$6.38M$634.0K—
Shareholders' equity−$81.7M−$87.6M$72.8M$36.0M$5.83M−$2.10M$7.68M$11.0M
Cash flow
Operating cash flow−$16.7M−$17.4M−$21.6M−$32.4M−$34.3M−$17.2M−$22.0M−$27.9M
Capital expenditure$3.07M$879.0K$781.0K$2.65M$1.77M$196.0K$76.0K$210.0K
Free cash flow−$19.8M−$18.2M−$22.4M−$35.0M−$36.1M−$17.4M−$22.0M−$28.1M

From PolyPid's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

PolyPid in the news

Nov 11, 2026 GlobeNewswire PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Oct 27, 2026 Investing.com Oppenheimer initiates PolyPid stock coverage with outperform rating Target

About PolyPid

Headquarters
Petach Tikva, Israel From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →